After a minor delay, GlaxoSmithKline PLC is prepared to launch Breo Ellipta (fluticasone/vilanterol), the first once-daily inhaled corticosteroid/long-acting beta2-agonist intended to eventually supplant AdvairDiskus as the world’s leading respiratory drug. Breo Ellipta will be available in the U.S. for chronic obstructive pulmonary disease before the end of October, Senior VP-Respiratory Jorge Bartolome said in an interview Oct. 8.
GSK Set For Breo Launch, But Access Will Require Time
GlaxoSmithKline will launch its once-daily COPD treatment Breo in the U.S. in October, Senior VP-Respiratory Jorge Bartolome said in an interview. The company will market Breo as the first once-daily ICS/LABA combination offering 24-hour lung function improvement. But already some payers are denying coverage.